Leica Biosystems Secures FDA Clearances to Expand Digital Pathology Portfolio

Leica Biosystems, a Danaher company, has announced multiple U.S. Food and Drug Administration 510(k) FDA clearances designed to strengthen its connected clinical digital pathology portfolio, including the industry’s first standalone, AI-assisted quality control software. These regulatory decisions are aimed at helping pathology laboratories deliver high-quality digital images with enhanced consistency and speed, supporting timely and […]

The post Leica Biosystems Secures FDA Clearances to Expand Digital Pathology Portfolio first appeared on HHM Global | B2B Online Platform & Magazine.